Literature DB >> 20028857

Alternative splicing of the cyclin D1 proto-oncogene is regulated by the RNA-binding protein Sam68.

Maria Paola Paronetto1, Manuela Cappellari, Roberta Busà, Simona Pedrotti, Roberta Vitali, Clay Comstock, Terry Hyslop, Karen E Knudsen, Claudio Sette.   

Abstract

Human cyclin D1 is expressed as two isoforms derived by alternate RNA splicing, termed D1a and D1b, which differ for the inclusion of intron 4 in the D1b mRNA. Both isoforms are frequently upregulated in human cancers, but cyclin D1b displays relatively higher oncogenic potential. The splicing factors that regulate alternative splicing of cyclin D1b remain unknown despite the likelihood that they contribute to cyclin D1 oncogenicity. In this study, we report that Sam68, an RNA-binding protein frequently overexpressed in prostate cancer cells, enhances splicing of cyclin D1b and supports its expression in prostate cancer cells. Chromatin immunoprecipitation and RNA coimmunoprecipitation experiments showed that Sam68 is recruited to the human CCND1 gene encoding cyclin D1 and that it binds to cyclin D1 mRNA. Transient overexpression and RNAi knockdown experiments indicated that Sam68 acts to enhance endogenous expression of cyclin D1b. Minigene reporter assays showed that Sam68 directly affected alternative splicing of CCND1 message, with a preference for the A870 allele that is known to favor cyclin D1b splicing. Sam68 interacted with the proximal region of intron 4, and its binding correlated inversely with recruitment of the spliceosomal component U1-70K. Sam68-mediated splicing was modulated by signal transduction pathways that elicit phosphorylation of Sam68 and regulate its affinity for CCND1 intron 4. Notably, Sam68 expression positively correlates with levels of cyclin D1b, but not D1a, in human prostate carcinomas. Our results identify Sam68 as the first splicing factor to affect CCND1 alternative splicing in prostate cancer cells, and suggest that increased levels of Sam68 may stimulate cyclin D1b expression in human prostate cancers.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20028857      PMCID: PMC2884274          DOI: 10.1158/0008-5472.CAN-09-2788

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  Physical and functional interaction between the transcriptional cofactor CBP and the KH domain protein Sam68.

Authors:  Wei Hong; Ross J Resnick; Carrie Rakowski; David Shalloway; Steven J Taylor; Gerd A Blobel
Journal:  Mol Cancer Res       Date:  2002-11       Impact factor: 5.852

2.  Signal-dependent regulation of splicing via phosphorylation of Sam68.

Authors:  Nathalie Matter; Peter Herrlich; Harald König
Journal:  Nature       Date:  2002-12-12       Impact factor: 49.962

3.  SUMO modification of Sam68 enhances its ability to repress cyclin D1 expression and inhibits its ability to induce apoptosis.

Authors:  I Babic; E Cherry; D J Fujita
Journal:  Oncogene       Date:  2006-03-27       Impact factor: 9.867

4.  Sik (BRK) phosphorylates Sam68 in the nucleus and negatively regulates its RNA binding ability.

Authors:  J J Derry; S Richard; H Valderrama Carvajal; X Ye; V Vasioukhin; A W Cochrane; T Chen; A L Tyner
Journal:  Mol Cell Biol       Date:  2000-08       Impact factor: 4.272

Review 5.  The development of androgen-independent prostate cancer.

Authors:  B J Feldman; D Feldman
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

6.  The RNA-binding protein Sam68 contributes to proliferation and survival of human prostate cancer cells.

Authors:  R Busà; M P Paronetto; D Farini; E Pierantozzi; F Botti; D F Angelini; F Attisani; G Vespasiani; C Sette
Journal:  Oncogene       Date:  2007-01-22       Impact factor: 9.867

Review 7.  Cyclin D1: polymorphism, aberrant splicing and cancer risk.

Authors:  K E Knudsen; J Alan Diehl; C A Haiman; E S Knudsen
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

8.  Cyclin D1b variant promotes cell invasiveness independent of binding to CDK4 in human bladder cancer cells.

Authors:  Chul Jang Kim; Kayoko Nishi; Takahiro Isono; Yusuke Okuyama; Yukihiro Tambe; Yusaku Okada; Hirokazu Inoue
Journal:  Mol Carcinog       Date:  2009-10       Impact factor: 4.784

9.  Profiling alternatively spliced mRNA isoforms for prostate cancer classification.

Authors:  Chaolin Zhang; Hai-Ri Li; Jian-Bing Fan; Jessica Wang-Rodriguez; Tracy Downs; Xiang-Dong Fu; Michael Q Zhang
Journal:  BMC Bioinformatics       Date:  2006-04-11       Impact factor: 3.169

10.  The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x.

Authors:  Maria Paola Paronetto; Tilman Achsel; Autumn Massiello; Charles E Chalfant; Claudio Sette
Journal:  J Cell Biol       Date:  2007-03-19       Impact factor: 10.539

View more
  83 in total

1.  MicroRNA (miRNA)-mediated interaction between leukemia/lymphoma-related factor (LRF) and alternative splicing factor/splicing factor 2 (ASF/SF2) affects mouse embryonic fibroblast senescence and apoptosis.

Authors:  Lorena Verduci; Marcella Simili; Milena Rizzo; Alberto Mercatanti; Monica Evangelista; Laura Mariani; Giuseppe Rainaldi; Letizia Pitto
Journal:  J Biol Chem       Date:  2010-10-04       Impact factor: 5.157

Review 2.  Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression.

Authors:  Alessia Locatelli; Kristopher A Lofgren; Andrea R Daniel; Nancy E Castro; Carol A Lange
Journal:  Horm Cancer       Date:  2012-04       Impact factor: 3.869

3.  Sam68 regulates cell proliferation and cell adhesion-mediated drug resistance (CAM-DR) via the AKT pathway in non-Hodgkin's lymphoma.

Authors:  Yaxun Wu; Xiaohong Xu; Xiaobing Miao; Xinghua Zhu; Haibing Yin; Yunhua He; Chunsun Li; Yushan Liu; Yali Chen; Xiaoyun Lu; Yuchan Wang; Song He
Journal:  Cell Prolif       Date:  2015-10-19       Impact factor: 6.831

4.  Clinical significance of Sam68 expression in endometrial carcinoma.

Authors:  Qingying Wang; Yue Li; Jianhong Zhou; Jie Liu; Jinlong Qin; Feng Xing; Jiawen Zhang; Jiajing Cheng
Journal:  Tumour Biol       Date:  2015-01-21

Review 5.  Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged.

Authors:  Charles J David; James L Manley
Journal:  Genes Dev       Date:  2010-11-01       Impact factor: 11.361

6.  High Sam68 expression predicts poor prognosis in non-small cell lung cancer.

Authors:  Z Zhang; Y Xu; N Sun; M Zhang; J Xie; Z Jiang
Journal:  Clin Transl Oncol       Date:  2014-02-13       Impact factor: 3.405

Review 7.  Faulty RNA splicing: consequences and therapeutic opportunities in brain and muscle disorders.

Authors:  Vittoria Pagliarini; Piergiorgio La Rosa; Claudio Sette
Journal:  Hum Genet       Date:  2017-04-22       Impact factor: 4.132

Review 8.  Cyclin D1, cancer progression, and opportunities in cancer treatment.

Authors:  Shuo Qie; J Alan Diehl
Journal:  J Mol Med (Berl)       Date:  2016-10-02       Impact factor: 4.599

9.  Convergence of oncogenic and hormone receptor pathways promotes metastatic phenotypes.

Authors:  Michael A Augello; Craig J Burd; Ruth Birbe; Christopher McNair; Adam Ertel; Michael S Magee; Daniel E Frigo; Kari Wilder-Romans; Mark Shilkrut; Sumin Han; Danielle L Jernigan; Jeffry L Dean; Alessandro Fatatis; Donald P McDonnell; Tapio Visakorpi; Felix Y Feng; Karen E Knudsen
Journal:  J Clin Invest       Date:  2012-12-21       Impact factor: 14.808

10.  Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene.

Authors:  Cristina Valacca; Serena Bonomi; Emanuele Buratti; Simona Pedrotti; Francisco Ernesto Baralle; Claudio Sette; Claudia Ghigna; Giuseppe Biamonti
Journal:  J Cell Biol       Date:  2010-09-27       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.